Ilya Rachman
Förmögenhet: 9 M $ per 2026-10-31
Förmögenhet: 9 M $ per 2026-10-31
Ilya Rachman is the founder of Immix Biopharma, Inc., founded in 2012, holding the title of Chairman & Chief Executive Officer.
Dr. Rachman currently holds the positions of Chief Executive Officer, Secretary, and Director at Nexcella, Inc. Education history includes an MBA from the University of California, Los Angeles; graduate and doctorate degrees from the University of Illinois; and an undergraduate degree from the University of Iowa.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
IMMIX BIOPHARMA, INC. 1,38 % | 2026-05-22 | 1 141 683 ( 1,38 % ) | 9 M $ | 2026-10-31 |
| Företag | Position | Start |
|---|---|---|
| IMMIX BIOPHARMA, INC. | Verkställande Direktör | 2012-01-01 |
Nexcella, Inc.
Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases | Verkställande Direktör | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immix Biopharma, Inc.
Immix Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for cancer patients | Health Technology |
Nexcella, Inc.
Nexcella, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell therapies for AL amyloidosis and immune-mediated diseases | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån